FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3216876256> ?p ?o ?g. }

• W3216876256 abstract "Background: Low-dose rivaroxaban and low-intensity warfarin are widely used in Asia for patients with atrial fibrillation (AF). However, in Asians, it is unclear whether low-dose rivaroxaban and low-intensity warfarin can improve the prognosis of AF. In this study, we investigate the survival benefits of low-dose rivaroxaban and low-intensity warfarin in Asian patients with AF in clinical practice. Methods: This cohort study used medical records in a single tertiary hospital in China, between 2019 and 2020, to identify patients with AF who used rivaroxaban or warfarin, or had no anticoagulant therapy. Follow-ups were performed through telephone contact or medical record review. Cox proportional hazards models were used to compare the risk of mortality of patients in the anticoagulant-untreated group vs. warfarin-treated groups and rivaroxaban-treated groups. Results: A total of 1727 AF patients, discharged between 2019 and 2020, were enrolled in this cohort, of which 873 patients did not use any anticoagulant, 457 patients received warfarin and 397 patients used rivaroxaban. Multivariable analysis showed that, of all the warfarin groups, patients with an international normalized ratio (INR) below 2, good INR control, or poor INR control had a significantly lower risk of mortality compared with that of patients without anticoagulants (HR 0.309, p = 0.0001; HR 0.387, p = 0.0238; HR 0.363, p &lt; 0.0001). Multivariable Cox proportional hazard analyses also demonstrated that, compared with the no anticoagulant group, all rivaroxaban dosage groups (≤10 mg, HR 0.456, p = 0.0129; 15 mg, HR 0.246, p = 0.0003; 20 mg, HR 0.264, p = 0.0237) were significantly associated with a lower risk of mortality. Conclusion: Despite effects being smaller than observed with recommended optimal anticoagulation, the use of warfarin with an INR below 2, poor INR control and the use of low-dose rivaroxaban may still provide survival benefits, suggesting viable alternatives that enable physicians to better resolve decisional conflicts concerning the risks and benefits of anticoagulant therapies, as well as for patients in need of but unable to receive standard anticoagulant therapy due to bleeding risk or other factors, such as financial burden, concerns of adverse outcomes, as well as low treatment compliance and persistence." @default.
• W3216876256 created "2021-12-06" @default.
• W3216876256 creator A5011923619 @default.
• W3216876256 creator A5022815488 @default.
• W3216876256 creator A5035637361 @default.
• W3216876256 creator A5039837625 @default.
• W3216876256 creator A5053672090 @default.
• W3216876256 creator A5060667885 @default.
• W3216876256 creator A5072105710 @default.
• W3216876256 creator A5086609279 @default.
• W3216876256 date "2021-11-25" @default.
• W3216876256 modified "2023-09-26" @default.
• W3216876256 title "Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?" @default.
• W3216876256 cites W2038090320 @default.
• W3216876256 cites W2044297239 @default.
• W3216876256 cites W2050118273 @default.
• W3216876256 cites W2050306424 @default.
• W3216876256 cites W2068476516 @default.
• W3216876256 cites W2070601915 @default.
• W3216876256 cites W2081205482 @default.
• W3216876256 cites W2085975373 @default.
• W3216876256 cites W2097854437 @default.
• W3216876256 cites W2127985968 @default.
• W3216876256 cites W2133435868 @default.
• W3216876256 cites W2136489990 @default.
• W3216876256 cites W2136587148 @default.
• W3216876256 cites W2170421103 @default.
• W3216876256 cites W2180920440 @default.
• W3216876256 cites W2253985091 @default.
• W3216876256 cites W2275653506 @default.
• W3216876256 cites W2320128544 @default.
• W3216876256 cites W2321584584 @default.
• W3216876256 cites W2472261290 @default.
• W3216876256 cites W2521940263 @default.
• W3216876256 cites W2551359113 @default.
• W3216876256 cites W2566947560 @default.
• W3216876256 cites W2588800208 @default.
• W3216876256 cites W2598370951 @default.
• W3216876256 cites W2740723077 @default.
• W3216876256 cites W2750762793 @default.
• W3216876256 cites W2761532891 @default.
• W3216876256 cites W2906512981 @default.
• W3216876256 cites W2938786224 @default.
• W3216876256 cites W2946158013 @default.
• W3216876256 cites W2973650400 @default.
• W3216876256 cites W2985625963 @default.
• W3216876256 cites W3004050106 @default.
• W3216876256 cites W3042846724 @default.
• W3216876256 cites W3082188176 @default.
• W3216876256 cites W3123126572 @default.
• W3216876256 cites W3146038544 @default.
• W3216876256 cites W3156427687 @default.
• W3216876256 cites W4205645630 @default.
• W3216876256 doi "https://doi.org/10.3389/fcvm.2021.768730" @default.
• W3216876256 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34901228" @default.
• W3216876256 hasPublicationYear "2021" @default.
• W3216876256 type Work @default.
• W3216876256 sameAs 3216876256 @default.
• W3216876256 citedByCount "1" @default.
• W3216876256 countsByYear W32168762562022 @default.
• W3216876256 crossrefType "journal-article" @default.
• W3216876256 hasAuthorship W3216876256A5011923619 @default.
• W3216876256 hasAuthorship W3216876256A5022815488 @default.
• W3216876256 hasAuthorship W3216876256A5035637361 @default.
• W3216876256 hasAuthorship W3216876256A5039837625 @default.
• W3216876256 hasAuthorship W3216876256A5053672090 @default.
• W3216876256 hasAuthorship W3216876256A5060667885 @default.
• W3216876256 hasAuthorship W3216876256A5072105710 @default.
• W3216876256 hasAuthorship W3216876256A5086609279 @default.
• W3216876256 hasBestOaLocation W32168762561 @default.
• W3216876256 hasConcept C126322002 @default.
• W3216876256 hasConcept C164705383 @default.
• W3216876256 hasConcept C207103383 @default.
• W3216876256 hasConcept C2776301958 @default.
• W3216876256 hasConcept C2778205648 @default.
• W3216876256 hasConcept C2778661090 @default.
• W3216876256 hasConcept C2779161974 @default.
• W3216876256 hasConcept C44249647 @default.
• W3216876256 hasConcept C50382708 @default.
• W3216876256 hasConcept C71924100 @default.
• W3216876256 hasConcept C72563966 @default.
• W3216876256 hasConceptScore W3216876256C126322002 @default.
• W3216876256 hasConceptScore W3216876256C164705383 @default.
• W3216876256 hasConceptScore W3216876256C207103383 @default.
• W3216876256 hasConceptScore W3216876256C2776301958 @default.
• W3216876256 hasConceptScore W3216876256C2778205648 @default.
• W3216876256 hasConceptScore W3216876256C2778661090 @default.
• W3216876256 hasConceptScore W3216876256C2779161974 @default.
• W3216876256 hasConceptScore W3216876256C44249647 @default.
• W3216876256 hasConceptScore W3216876256C50382708 @default.
• W3216876256 hasConceptScore W3216876256C71924100 @default.
• W3216876256 hasConceptScore W3216876256C72563966 @default.
• W3216876256 hasLocation W32168762561 @default.
• W3216876256 hasLocation W32168762562 @default.
• W3216876256 hasLocation W32168762563 @default.
• W3216876256 hasLocation W32168762564 @default.
• W3216876256 hasLocation W32168762565 @default.
• W3216876256 hasOpenAccess W3216876256 @default.
• W3216876256 hasPrimaryLocation W32168762561 @default.
• W3216876256 hasRelatedWork W1977378072 @default.

• next